Analysis of an oligonucleotide N3′→ P5′ phosphoramidate/phosphorothioate chimera with capillary gel electrophoresis

N3′→ P5′ phosphoramidate/phosphorothioate chimeric oligonucleotides (ODNs) are presently under investigation as potential antisense drugs. Within the field of antisense research, “second generation” chimeric ODNs have exhibited improved characteristics relative to oligonucleotides with uniformly modified backbones. The ODN of interest for this study consisted of a chemically synthesized 18‐mer of mixed nucleotide base sequence with a backbone consisting of eight central phosphorothioate linkages flanked by four N3′→ P5′ phosphoramidate (amidate) linkages on the 5′‐end and five amidate linkages ont he 3′‐end. This chimera presents analytical challenges due to the central phosphorothioate region. Here, we present a capillary gel electrophoresis (CGE) method for the analysis of the above N3′→ P5′ phosphoramidate/phosphorothioate chimera. CGE was used to analyze the product prior to its purification by reversed phase ‐ high performance liquid chromatography (RP‐HPLC), and each fraction collected from the purification was similarly analyzed. An internal standard was utilized to determine the relative mobility of our product, and polyacrylamide gel electrophoresis (PAGE) analysis was used to verify CGE results.

[1]  S. Mccurdy,et al.  An improved synthesis of oligodeoxynucleotide N3'-->P5' phosphoramidates and their chimera using hindered phosphoramidite monomers and a novel handle for reverse phase purification. , 1998, Nucleic acids research.

[2]  S. Mccurdy,et al.  N3'-->P5' Oligodeoxyribonucleotide Phosphoramidates: A New Method of Synthesis Based on a Phosphoramidite Amine-Exchange Reaction. , 1997, The Journal of organic chemistry.

[3]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Nerenberg,et al.  RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates. , 1997, Nucleic acids research.

[5]  S. Mccurdy,et al.  An improved method for the synthesis of N3′→P5′ phosphoramidate oligonucleotides , 1997 .

[6]  M. Matteucci.  Structural modifications toward improved antisense oligonucleotides , 1996 .

[7]  D. Szymkowski,et al.  Developing antisense oligonucleotides from the laboratory to clinical trials , 1996 .

[8]  D. Fabbro,et al.  Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. , 1996, Biochemical Society transactions.

[9]  D. Lloyd,et al.  Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs. , 1996, Journal of chromatography. A.

[10]  D. Spiller,et al.  Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. , 1995, Blood.

[11]  L. DeDionisio,et al.  Analysis of a ribonuclease H digestion of N3'-->P5' phosphoramidate-RNA duplexes by capillary gel electrophoresis. , 1995, Journal of chromatography. B, Biomedical applications.

[12]  R. H. Carlson,et al.  Quantitative capillary gel electrophoresis assay of phosphorothioate oligonucleotides in pharmaceutical formulations. , 1994, Journal of chromatography. A.

[13]  M. Vilenchik,et al.  High-performance liquid chromatography and capillary gel electrophoresis as applied to antisense DNA , 1993 .

[14]  E. Uhlmann,et al.  Antisense oligonucleotides: a new therapeutic principle , 1990 .